Revolution Medicines, Inc. (NASDAQ:RVMD – Get Rating) – SVB Leerink decreased their Q2 2023 earnings per share estimates for Revolution Medicines in a report released on Monday, May 8th. SVB Leerink analyst J. Chang now forecasts that the company will post earnings of ($0.85) per share for the quarter, down from their prior forecast of […]
Revolution Medicines (NASDAQ:RVMD – Get Rating) posted its earnings results on Monday. The company reported ($0.72) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.12, Briefing.com reports. Revolution Medicines had a negative net margin of 744.36% and a negative return on equity of 41.68%. The business had revenue of […]
Revolution Medicines (NASDAQ:RVMD – Get Rating) is set to release its earnings data after the market closes on Monday, May 8th. Analysts expect Revolution Medicines to post earnings of ($0.84) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link. Revolution Medicines (NASDAQ:RVMD […]
Revolution Medicines, Inc. (NASDAQ:RVMD – Get Rating) – HC Wainwright raised their Q1 2023 earnings estimates for Revolution Medicines in a report released on Wednesday, April 12th. HC Wainwright analyst R. Burns now expects that the company will earn ($0.78) per share for the quarter, up from their previous estimate of ($0.92). HC Wainwright currently […]
Shares of Revolution Medicines, Inc. (NASDAQ:RVMD – Get Rating) have earned a consensus rating of “Moderate Buy” from the eight analysts that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 1-year price target […]